Methods of treatment using conditional superagonist CTL ligands for the promotion of tumor-specific CTL responses
View Patent ↗What is described is a method of treatment of a patient with a tumor, comprising administering a cell responsive to a peptide comprising a tumor epitope, wherein the tumor epitope comprises an amino acid substitution in a tumor antigen. The tumor antigen is preferably selected from the group consisting of NYESO-I 157-165 , NYESO-II 157-170 , or MART-1 26-35 , preferably SEQ ID NOS: 1-351, 361-376, and 392-401.
1. A method of treatment of a patient with a tumor, comprising administering a cell responsive to a peptide comprising a tumor epitope, wherein the tumor epitope comprises a sequence selected from the group consisting of SEQ ID NOS: 363-365 and 368-375.
2. The method of claim 1 , wherein the tumor epitope comprises a sequence selected from the group consisting of SEQ ID NOS: 368-375.
3. The method of claim 2 , wherein the tumor epitope comprises a sequence consisting of SEQ ID NOS: 372, 374, or 375.
4. The method of claim 1 , wherein the tumor epitope comprises a sequence selected from the group consisting of SEQ ID NOS: 363-365.
5. The method of claim 4 , wherein the tumor epitope comprises a sequence selected from the group consisting of SEQ ID NOS: 363 and 365.
6. The method of claim 1 , wherein the tumor epitope comprises a multiplicity of sequences selected from the group consisting of SEQ ID NOS: 363-365 and 368-375.
7. The method of claim 6 , wherein the tumor epitope comprises a multiplicity of sequences selected from the group consisting of SEQ ID NOS: 363-365.
8. The method of claim 7 , wherein the tumor epitope comprises a sequence selected from the group consisting of SEQ ID NOS: 363 and 365.
9. The method of claim 6 , wherein the tumor epitope comprises a multiplicity of sequences selected from the group consisting of SEQ ID NOS: 368-375.
10. The method of claim 9 , wherein the tumor epitope comprises a sequence selected from the group consisting of SEQ ID NOS: 372, 374, and 375.
11. A method of treating a patient with a tumor, comprising administering a pharmaceutical composition to said patient, wherein said pharmaceutical composition comprising a peptide comprising a tumor epitope, wherein the tumor epitope comprises a sequence selected from the group consisting of SEQ ID NOS: 363-365 and 368-375.
12. The method of claim 11 , wherein the tumor epitope comprises a sequence selected from the group consisting of SEQ ID NOS: 368-375.
13. The method of claim 12 , wherein the tumor epitope comprises a sequence selected from the group consisting of SEQ ID NOS: 372, 374, and 375.
14. The method of claim 11 , wherein the tumor epitope comprises a sequence selected from the group consisting of SEQ ID NOS: 363-365.
15. The method of claim 14 , wherein the tumor epitope comprises a sequence selected from the group consisting of SEQ ID NOS: 363 and 365.
16. The method of claim 11 , wherein the tumor epitope comprises a multiplicity of sequences selected from the group consisting of SEQ ID NOS: 363-365 and 368-375.
17. The method of claim 16 , wherein the tumor epitope comprises a multiplicity of sequences selected from the group consisting of SEQ ID NOS: 363-365.
18. The method of claim 17 , wherein the tumor epitope comprises a sequence selected from the group consisting of SEQ ID NOS: 363 and 365.
19. The compound of claim 16 , wherein the tumor epitope comprises a multiplicity of sequences selected from the group consisting of SEQ ID NOS: 368-375.
20. The compound of claim 19 , wherein the tumor epitope comprises a sequence selected from the group consisting of SEQ ID NOS: 372, 374, and 375.